27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Patients on galantamine had longer mean persistence and better adherence compared with patients on donepezil, with a hazard ratio for discontinuation of 0.91 [95% confidence interval (CI) 0.87-0.96] and a relative risk for good adherence of 1.01 (95% CI 1.002-1.03). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Anti-dementia medications are widely prescribed to patients with Alzheimer's dementia (AD) in South Korea. 5 key findings →
Participants: 8,653 Evidence: low
Full summary, score breakdown and related studies → Original source
Between January 2006 and December 2010, 20,729 patients aged >70 years received a prescription for an AD medication. 5 key findings →
Participants: 20,729 Evidence: low
Full summary, score breakdown and related studies → Original source
Nursing homes underreport their antipsychotic prescribing levels, on average, by 1 percentage point per quarter relative to Medicare Part D claims (0.013, 95% confidence interval (CI), 0.012-0.015; p<.001). 5 key findings →
Participants: 586,281 Evidence: low
Full summary, score breakdown and related studies → Original source
Baseline demographics were similar between the treatment groups. 5 key findings →
Participants: 144 Evidence: high
Full summary, score breakdown and related studies → Original source
There were no group differences with any of the outcome measures in an intent-to-treat analysis. 5 key findings →
Participants: 41 Evidence: high
Full summary, score breakdown and related studies → Original source
In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients. 5 key findings →
Participants: 215 Evidence: low
Full summary, score breakdown and related studies → Original source
The use of anticholinergic medications among patients with OAB was associated with an increased risk of new-onset dementia compared to beta-3 agonist users. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients who started ChEI therapy after the introduction of the coverage policy had a significantly longer persistence. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Overall, 74 studies containing 92 cases were found of MDs related to ACHEIs. 5 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
No statistically significant improvement in the primary outcome measures (MMSE and ADAS-Cog) was observed with drug therapy at 36 weeks, at which point all groups had lost, on average, 1 point on the MMSE and gained 2-3 points on the ADAS-Cog scale compared with baseline. 5 key findings →
Participants: 938 Evidence: high
Full summary, score breakdown and related studies → Original source
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed. 5 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source
Inappropriate drug use was common in our study cohort. 4 key findings →
Participants: 519 Evidence: moderate
Full summary, score breakdown and related studies → Original source
At weeks 12 and 24/28, ITT analysis demonstrated that memantine treatment produced statistically significant benefits over placebo treatment in NPI total score (p=0.001 and p=0.008), and in NPI single items: delusions (p=0.007 week 12, p=0.001 week 24/28), hallucinations (p=0.037 week 12), agitation/aggression (p=0.001 week 12, p=0.001 week 24/28), and irritability/lability (p=0.005 week 24/28), LOCF population. 4 key findings →
Participants: 2,311 Evidence: high
Full summary, score breakdown and related studies → Original source
Use of cholinesterase inhibitors is associated with increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture in older adults with dementia. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Utilization patterns of psychotropic drugs in institutionalized patients with dementia have changed over the past decade. 4 key findings →
Participants: 49,251 Evidence: low
Full summary, score breakdown and related studies → Original source
After taking into consideration a possible protopathic bias in the 2 years preceding the AD diagnosis date, benzodiazepine use was not associated with an increased risk of developing AD. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Overall, 304 patients receiving cholinesterase inhibitors/memantine also received anticholinergics. 5 key findings →
Participants: 304 Evidence: low
Full summary, score breakdown and related studies → Original source
We found that 51.9% of DLB patients were ever prescribed a ChEI, and those who were prescribed a ChEI had a greater diagnosis interval. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. 4 key findings →
Design: clinical trial Participants: 684 Evidence: high
Full summary, score breakdown and related studies → Original source
Subjects taking antihypertensive medication (n = 651, 83.9% of whom took diuretics) had a lower prevalence of dementia than those not taking antihypertensive medication (P<.001). 5 key findings →
Participants: 651 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The efficacy of the ginkgo biloba special extract EGb 761 in outpatients with presenile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) according to DSM-III-R was investigated in a prospective, randomized, double-blind, placebo-controlled, multi-center study. 2 key findings →
Participants: 216 Evidence: high
Full summary, score breakdown and related studies → Original source
Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). 5 key findings →
Design: open-label trial Participants: 2,446 Evidence: low
Full summary, score breakdown and related studies → Original source
In total, 100 subjects completed the study. 5 key findings →
Design: clinical trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Two‐hundred and sixteen only subjects were randomized across 28 French expert clinical sites. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →